Home> Products> other sulfonylureas

{ "products": [ { "_id": "68d51d9a26579f4bc195771a", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Glimepiride IP1 mg, Voglibose IP 0.2 MG & Metformin Hydrochloride IP 500 mg ", "description": "GLIMITERIS MV1 0.2 is an advanced fixed-dose combination (FDC) medication designed for adults with Type 2 Diabetes Mellitus (T2DM) who require more than lifestyle modifications or single/dual therapy to maintain optimal blood sugar levels. This innovative formulation brings together the power of three well-established antidiabetic agents—Glimepiride (1 mg), Voglibose (0.2 mg), and Metformin Hydrochloride SR (500 mg)—to provide comprehensive glycemic control.\n\nIt is particularly effective for patients struggling with postprandial hyperglycemia, fasting glucose regulation, and HbA1c reduction, making it a preferred choice in cases of poorly controlled diabetes.\n\n \n\nMechanism of Action\nThe therapeutic benefit of GLIMITERIS MV1 0.2 comes from the unique synergy of its three components, each targeting different aspects of glucose metabolism:\n\n1. Glimepiride (1 mg) – Sulfonylurea\nStimulates insulin secretion by activating pancreatic beta cells.\n\nProvides a long-lasting effect with comparatively lower hypoglycemia risk than older sulfonylureas.\n\nHelps reduce both fasting and postprandial glucose levels.\n\n2. Voglibose (0.2 mg) – Alpha-Glucosidase Inhibitor\nDelays the breakdown and absorption of carbohydrates in the intestine.\n\nMinimizes post-meal glucose spikes (PPBG).\n\nActs locally in the gut and has minimal systemic absorption, which reduces systemic side effects.\n\n3. Metformin Hydrochloride SR (500 mg) – Biguanide\nDecreases hepatic glucose production (gluconeogenesis).\n\nImproves peripheral insulin sensitivity, enhancing glucose uptake in muscles.\n\nDoes not cause hypoglycemia on its own.\n\nThe sustained-release (SR) formulation ensures extended control and reduces gastrointestinal side effects.\n\n \n\nIndications\nGLIMITERIS MV1 0.2 is indicated for:\n\nAdults with Type 2 Diabetes Mellitus.\n\nPatients inadequately controlled with monotherapy or dual therapy.\n\nManagement of fasting and postprandial hyperglycemia.\n\nLong-term HbA1c reduction as part of a comprehensive diabetes care plan.\n\n \n\nKey Benefits\n✅ Comprehensive Blood Sugar Control – Acts on fasting, post-meal, and long-term HbA1c levels.\n✅ Postprandial Spike Management – Voglibose effectively controls carbohydrate-induced sugar surges.\n✅ Reduced Pill Burden – Combines three medicines into a single tablet.\n✅ Lower Hypoglycemia Risk – Metformin and Voglibose balance out Glimepiride’s insulin-secreting effect.\n✅ Weight Management Support – Metformin may promote modest weight loss or prevent weight gain.\n✅ Improved Tolerability – SR formulation of Metformin enhances gastrointestinal comfort.\n\n \n\nDosage and Administration\nRecommended dose: One tablet once or twice daily with meals, or as directed by the physician.\n\nAdministration tips:\n\nTake with the first bite of a main meal to maximize Voglibose’s effect.\n\nSwallow whole with water; do not crush or chew the SR tablet.\n\nDose adjustments: Based on blood sugar monitoring, clinical response, and renal/hepatic function.\n\n \n\nContraindications\nGLIMITERIS MV1 0.2 is not suitable for patients with:\n\nType 1 diabetes or diabetic ketoacidosis.\n\nSevere renal impairment (eGFR <30 mL/min/1.73 m²).\n\nHepatic dysfunction.\n\nSevere gastrointestinal diseases.\n\nHistory of lactic acidosis.\n\nHypersensitivity to Glimepiride, Voglibose, or Metformin.\n\nPregnancy and lactation (unless strictly advised by a physician).\n\n \n\nWarnings and Precautions\nHypoglycemia: Risk is higher when combined with other antidiabetics or with missed meals.\n\nLactic Acidosis: A rare but life-threatening effect of Metformin—renal function monitoring is essential.\n\nGI Side Effects: Voglibose and Metformin may cause bloating, flatulence, or diarrhea (usually temporary).\n\nVitamin B12 Monitoring: Long-term Metformin use may reduce B12 absorption.\n\nLiver and Kidney Function: Regular monitoring is recommended for safe long-term use.\n\n \n\nAdverse Effects\nCommon:\nGlimepiride: Mild hypoglycemia, dizziness, slight weight gain.\n\nVoglibose: Gas, abdominal discomfort, mild diarrhea.\n\nMetformin SR: Nausea, bloating, metallic taste, loose stools.\n\nRare but Serious:\nLactic acidosis (from Metformin).\n\nSevere hypoglycemia (especially if meals are skipped).\n\nAllergic reactions such as rash, itching, or swelling.\n\nElevated liver enzymes.\n\nSeek medical attention if symptoms such as rapid breathing, confusion, severe fatigue, or muscle pain occur.\n\n \n\nDrug Interactions\nIncreased hypoglycemia risk: With insulin, beta-blockers, and sulfonylureas.\n\nReduced Metformin efficacy: With corticosteroids, estrogens, and diuretics.\n\nLactic acidosis risk: Higher with alcohol or iodinated contrast agents. ", "price": 263.0, "discountamount": 80.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2182, "imageuri": "https://productimages.withfloats.com/actual/68d51d9cdf1a4ca2c252370a.png", "tileimageuri": "https://productimages.withfloats.com/tile/68d51d9cdf1a4ca2c252370a.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-09-25T10:46:50.098Z", "updatedon": "2025-10-02T11:20:20.402Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/glimepiride-ip1-mg-voglibose-ip-0-2-mg-metformin-hydrochloride-ip-500-mg-/2182", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIMITERIS MV1 0.2", "category": "", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68b0256b813270ffac595cb0", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRELAQWK 100", "description": "TRELAQWK 100 is an advanced oral antidiabetic medication containing Trelagliptin 100 mg, specifically designed for adults with type 2 diabetes mellitus (T2DM). Belonging to the class of Dipeptidyl Peptidase-4 (DPP-4) inhibitors, this formulation helps improve blood glucose control when used along with a proper diet and regular exercise.\nWith its once-weekly dosage regimen, TRELAQWK 100 offers a convenient treatment option, enhancing patient compliance and simplifying long-term diabetes management.\nKey Ingredient\nTrelagliptin 100 mg\nA long-acting DPP-4 inhibitor that regulates blood glucose levels by enhancing incretin hormones. These incretins stimulate insulin secretion and suppress glucagon release, helping to achieve better glycemic control.\nKey Benefits of TRELAQWK 100\nWeekly dosing ensures greater convenience and adherence\nReduces both fasting and postprandial blood sugar levels\nSupports natural blood sugar regulation without weight gain\nLow risk of hypoglycemia, especially when used as monotherapy or with non-insulin therapies\nCan be prescribed as monotherapy or in combination with other antidiabetic agents like metformin or sulfonylureas\nHow TRELAQWK 100 Works\nTRELAQWK 100 functions by blocking the DPP-4 enzyme, which normally degrades incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide).\nThese incretin hormones:\nStimulate insulin secretion in response to meals\nReduce glucagon release, lowering blood sugar levels\nThanks to its extended half-life, trelagliptin allows for once-weekly dosing, unlike other DPP-4 inhibitors that require daily administration.\nDirections for Use\nDosage: Take one tablet of TRELAQWK 100 once weekly, or as directed by your physician\nAdministration: May be taken with or without food, ideally on the same day each week\nMissed dose: Do not double the dose; consult your healthcare provider for guidance\nPossible Side Effects\nTRELAQWK 100 is usually well-tolerated, but some individuals may experience:\nMild headache\nNasopharyngitis (common cold-like symptoms)\nConstipation\nUpper respiratory tract infections\nRare skin allergies (rash, itching)\n👉 If you experience persistent abdominal pain, severe rashes, or symptoms suggestive of pancreatitis, stop the medication and seek medical care immediately.", "price": 550.0, "discountamount": 165.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2166, "imageuri": "https://productimages.withfloats.com/actual/68b0256ebb42c3d551ad314c.png", "tileimageuri": "https://productimages.withfloats.com/tile/68b0256ebb42c3d551ad314c.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-08-28T09:46:19.602Z", "updatedon": "2025-08-28T09:46:19.602Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trelaqwk-100/2166", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "trelagliptin 100 mg", "category": "DIABETIC RANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6890aa548a215c65672372e1", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "EMPATECH LINA 25/5", "description": "EMPATECH LINA 25/5 is a pharmaceutical tablet containing a combination of two active ingredients: Empagliflozin 25MG and Linagliptin 5MG. This medication is designed to help manage blood sugar levels in adults with type 2 diabetes mellitus. The combination works through complementary mechanisms to improve glycemic control more effectively than either drug alone. Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that promotes the excretion of excess glucose through urine, while Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances insulin secretion and suppresses glucagon release, particularly after meals. EMPATECH LINA 25/5 is generally prescribed alongside a balanced diet and regular exercise to optimize blood sugar management and reduce the risk of diabetes-related complications such as kidney damage, neuropathy, and cardiovascular issues.\n\nWhat is EMPATECH LINA 25/5?\n\nEMPATECH LINA 25/5 is a prescription medication combining Empagliflozin (25MG) and Linagliptin (5MG) tablets used to manage type 2 diabetes. It helps control elevated blood sugar levels by using dual actions — the removal of glucose via kidneys and improving pancreatic hormone responses. This combination aims to achieve better and sustained glycemic control, often necessary for patients who have inadequate blood sugar control with other treatments.\n\nUses of EMPATECH LINA 25/5\n\nTo improve blood sugar control in adults with type 2 diabetes, particularly when monotherapy is insufficient.\n\nOften used as a second-line therapy after metformin or when metformin is not tolerated.\n\nTo reduce HbA1c (hemoglobin A1c), an important measure of long-term glucose control.\n\nMay help reduce weight and blood pressure as empagliflozin aids in glucose excretion.\n\nSupports comprehensive diabetes management along with diet and exercise.\n\nPrevents or reduces the risk of diabetes-associated complications such as kidney disease, cardiovascular events, and nerve damage.\n\nSide Effects of EMPATECH LINA 25/5\n\nCommon side effects may include urinary tract infections and genital infections due to increased glucose in urine.\n\nIncreased urination and dehydration.\n\nDizziness or lightheadedness, especially when standing up quickly.\n\nHypoglycemia (low blood sugar), though rare with this combination.\n\nGastrointestinal symptoms such as nausea or diarrhea.\n\nPotential increased risk of ketoacidosis (a serious condition related to high blood acids) in rare cases.\n\nAllergic reactions, although uncommon, may occur and require prompt medical attention.\n\nPrecautions Before Using EMPATECH LINA 25/5\n\nInform your healthcare provider if you have kidney disease, liver problems, or a history of urinary tract infections.\n\nNot recommended for type 1 diabetes or diabetic ketoacidosis treatment.\n\nUse with caution if you are pregnant, planning to become pregnant, or breastfeeding.\n\nStay hydrated while on this medication to reduce the risk of dehydration and dizziness.\n\nInform your doctor about any history of pancreatitis or pancreas disorders.\n\nRegular monitoring of kidney function and blood sugar levels is advised during treatment.\n\nAvoid drinking excessive alcohol as it may increase side effects or risk of ketoacidosis.\n\nDrug Interactions: What Drugs Interact with EMPATECH LINA 25/5?\n\nOther antidiabetic medications, such as insulin or sulfonylureas, may increase the risk of hypoglycemia.\n\nDiuretics, blood pressure medications, and lithium may interact and increase side effects.\n\nDrugs that impair kidney function can affect empagliflozin’s efficacy and safety.\n\nCertain enzyme-inducing drugs may reduce linagliptin levels, lowering its effectiveness.\n\nConsult your healthcare provider for a full list of possible interactions and before starting any new medication, including over-the-counter drugs or supplements.\n\nConclusion\n\nEMPATECH LINA 25/5, containing Empagliflozin 25MG and Linagliptin 5MG, is an effective combination medication to treat high blood sugar levels caused by type 2 diabetes. Its dual-action approach targets different physiological mechanisms to improve blood glucose control, helping reduce the risks and complications associated with diabetes. While it is generally well-tolerated, awareness of possible side effects and drug interactions is important. Always use under medical supervision, alongside lifestyle modifications such as diet and exercise, for optimal diabetes management.", "price": 345.0, "discountamount": 104.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2154, "imageuri": "https://productimages.withfloats.com/actual/6890aa58dd0bc098c3220f4c.png", "tileimageuri": "https://productimages.withfloats.com/tile/6890aa58dd0bc098c3220f4c.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-08-04T12:40:52.619Z", "updatedon": "2025-08-04T12:40:52.619Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/empatech-lina-25-5/2154", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Empagliflozin and Linagliptin Tablets", "category": "DIABETIC RANGE", "tags": [ "Empagliflozin and Linagliptin Tablets" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6842b8014256f7114dfbd884", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRELAQWK 100", "description": "Trelagliptin 100mg in TRELAQWK 100 is an innovative once-weekly oral medication formulated with Trelagliptin 100mg, specifically designed to support adults in managing type 2 diabetes mellitus (T2DM). As a member of the Dipeptidyl Peptidase-4 (DPP-4) inhibitor class, it provides a simplified and effective approach to improving glycemic control when combined with a healthy diet and regular exercise. Its weekly dosing schedule enhances treatment adherence, offering a more sustainable option for long-term diabetes care.\n\nActive Ingredient:\nTrelagliptin 100mg\nA potent, long-acting DPP-4 inhibitor that helps maintain stable blood glucose levels by preserving incretin activity. Incretins are natural hormones that promote insulin release and suppress glucagon, playing a vital role in blood sugar regulation.\n\nCore Benefits:\nConvenient once-weekly dosing enhances patient compliance\n\nEffectively lowers both fasting and postprandial (after-meal) blood sugar\n\nPromotes natural insulin production without contributing to weight gain\n\nCarries a low risk of hypoglycemia, especially when not used with insulin\n\nCan be used alone or in combination with other antidiabetic medications like metformin or sulfonylureas\n\nMechanism of Action:\nTRELAQWK 100 works by blocking the DPP-4 enzyme, which normally degrades incretin hormones such as GLP-1 and GIP. These hormones play a crucial role in regulating blood sugar after meals. By prolonging their activity, Trelagliptin enhances insulin secretion and reduces glucagon levels, resulting in improved glycemic control. Its extended half-life allows for once-a-week administration, setting it apart from daily DPP-4 inhibitors.\n\nDosage & Administration:\nRecommended Dose: One tablet per week, or as advised by your doctor\n\nHow to Take: With or without food, preferably on the same day each week\n\nIf a dose is missed, do not double the next dose; seek guidance from your healthcare provider\n\nPossible Side Effects:\nTRELAQWK 100 is generally safe and well-tolerated. Some individuals may experience:\n\nHeadache\n\nNasopharyngitis (mild cold symptoms)\n\nConstipation\n\nUpper respiratory tract infections\n\nRare allergic reactions such as rashes or skin irritation\n\nSeek immediate medical advice if you experience unusual symptoms such as severe abdominal pain, persistent skin reactions, or signs of pancreatitis.", "price": 3.0, "discountamount": 1.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "medical advice", "generally safe", "healthcare provider", "food preferably", "extended halflife", "crucial role", "dpp4 enzyme", "sulfonylureas mechanism", "antidiabetic medications", "low risk", "vital role", "sustainable option", "regular exercise", "healthy diet", "effective approach", "support adults", "trelaqwk 100trelaqwk 100", "hormones play", "natural hormones", "dose seek guidance", "promote insulin release", "degrades incretin hormones", "experience unusual symptoms", "skin irritation seek", "onceaweek administration setting", "improved glycemic control", "regulating blood sugar", "weight gain carries", "suppress glucagon playing", "improving glycemic control" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2132, "imageuri": "https://productimages.withfloats.com/actual/6842b80c8a53ae8db15a02ac.png", "tileimageuri": "https://productimages.withfloats.com/tile/6842b80c8a53ae8db15a02ac.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-06-06T09:42:25.371Z", "updatedon": "2025-06-11T11:17:09.096Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trelaqwk-100/2132", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Trelagliptin 100mg", "category": "DIABETIC RANGE", "tags": [ "Trelagliptin side effects", "Trelagliptin brand name", "Trelagliptin brands in India", "Trelagliptin uses", "Trelagliptin 100mg" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "668e8611b9f7300708fe1240", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRIOGLIMITERIS 1/0.2 ", "description": "TRIOGLIMITERIS 1/0.2 \nVoglibose 0.2 mg, Glimepiride 1 mg & Metformin Hydrochloride 500 mg\nIntroduction\n\nTRIOGLIMITERIS 1/0.2 is a combination medication containing Voglibose, Glimepiride, and Metformin Hydrochloride. It is primarily used in the management of type 2 diabetes mellitus to improve glycemic control through different mechanisms of action targeting glucose metabolism.\n\nComposition\n\nVoglibose (0.2 mg): An alpha-glucosidase inhibitor that delays the digestion of carbohydrates in the intestine, thereby reducing postprandial blood glucose levels.\nGlimepiride (1 mg): A sulfonylurea derivative that stimulates insulin release from pancreatic beta cells, enhancing glucose uptake in peripheral tissues.\nMetformin Hydrochloride (500 mg): A biguanide that decreases hepatic glucose production, improves insulin sensitivity in peripheral tissues, and reduces intestinal glucose absorption.\nMechanism of Action\n\nTRIOGLIMITERIS 1/0.2 combines the actions of its components to achieve optimal glycemic control:\n\nVoglibose: Inhibits alpha-glucosidase enzymes in the intestine, delaying carbohydrate digestion and reducing the absorption of glucose after meals.\nGlimepiride: Stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner, thereby lowering blood glucose levels.\nMetformin Hydrochloride: Decreases hepatic glucose production through suppression of gluconeogenesis and enhances peripheral glucose uptake and utilization by improving insulin sensitivity.\nIndications\n\nTRIOGLIMITERIS 1/0.2 is indicated for:\n\nType 2 Diabetes Mellitus: Used to improve glycemic control in adults when diet, exercise, and monotherapy with metformin or sulfonylureas alone are not sufficient.\nDosage and Administration\n\nThe typical dosage of TRIOGLIMITERIS 1/0.2 is one tablet taken orally with meals, usually once or twice daily.\nDosage adjustments may be required based on individual patient response, blood glucose levels, and renal function.\nIt is essential to adhere to the prescribed dosage regimen to achieve optimal therapeutic outcomes.\nSide Effects\n\nCommon side effects of TRIOGLIMITERIS 1/0.2 may include:\n\nHypoglycemia (especially when used in combination with insulin or other antidiabetic medications)\nGastrointestinal disturbances (such as nausea, vomiting, diarrhea, or abdominal discomfort)\nWeight gain (mainly associated with sulfonylureas)\nMore severe side effects can include:\n\nAllergic reactions (rash, itching, swelling)\nLactic acidosis (rare but serious adverse effect associated with metformin use)\nHepatic dysfunction (monitor liver function tests periodically)\nPrecautions\n\nUse with caution in patients with renal impairment, hepatic dysfunction, or other significant medical conditions that may affect drug metabolism or excretion.\nRegular monitoring of blood glucose levels, renal function, and liver function is recommended during treatment with TRIOGLIMITERIS 1/0.2.\nAvoid use in patients with type 1 diabetes mellitus or diabetic ketoacidosis.\nDrug Interactions\n\nTRIOGLIMITERIS 1/0.2 may interact with other medications affecting blood glucose levels, such as insulin, other oral antidiabetic agents, or drugs that affect renal function or hepatic metabolism. Close monitoring and dose adjustments may be necessary.\nConclusion\n\nTRIOGLIMITERIS 1/0.2 provides a comprehensive approach to managing type 2 diabetes mellitus by combining Voglibose, Glimepiride, and Metformin Hydrochloride. This combination targets different aspects of glucose metabolism, enhancing insulin secretion, reducing hepatic glucose production, and delaying carbohydrate absorption in the intestine. Proper dosage, administration, and monitoring for side effects are essential to achieve and maintain optimal glycemic control in diabetic patients using TRIOGLIMITERIS 1/0.2. Consultation with a healthcare provider is recommended for personalized treatment plans and management of diabetes with this medication.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n", "price": 195.0, "discountamount": 58.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "500 mg", "0.2 mg", "one tablet", "Weight gain", "Glimepiride 1", "metformin use", "Proper dosage", "Glimepiride (1", "dosage regimen", "typical dosage", "renal function", "insulin release", "drug metabolism", "Lactic acidosis", "Close monitoring", "dose adjustments", "renal impairment", "diabetic patients", "insulin secretion", "different aspects", "Drug Interactions", "other medications", "Regular monitoring", "Dosage adjustments", "Allergic reactions", "peripheral tissues", "hepatic metabolism", "glucose metabolism", "insulin sensitivity", "healthcare provider", "Hepatic dysfunction", "Common side effects", "abdominal discomfort", "different mechanisms", "liver function tests", "diabetic ketoacidosis", "pancreatic beta cells", "combination medication", "carbohydrate digestion", "comprehensive approach", "serious adverse effect", "Metformin Hydrochloride", "carbohydrate absorption", "sulfonylurea derivative", "glucose-dependent manner", "optimal glycemic control", "type 1 diabetes mellitus", "type 2 diabetes mellitus", "More severe side effects", "alpha-glucosidase enzymes", "peripheral glucose uptake", "hepatic glucose production", "alpha-glucosidase inhibitor", "individual patient response", "personalized treatment plans", "optimal therapeutic outcomes", "Gastrointestinal disturbances", "intestinal glucose absorption", "other antidiabetic medications", "other oral antidiabetic agents", "postprandial blood glucose levels", "other significant medical conditions" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1939, "imageuri": "https://productimages.withfloats.com/actual/668e86143a68154e11e7d822.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668e86143a68154e11e7d822.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-10T13:01:05.875Z", "updatedon": "2024-07-10T13:01:05.875Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trioglimiteris-1-0-2-/1939", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TRIOGLIMITERIS 1/0.2 ", "category": "DIABETIC RANGE", "tags": [ "glimepiride 1mg+metformin 500mg+voglibose 0.2 mg", "Glimepiride 2mg Metformin 500mg Voglibose 0.2 mg b", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg", "voglibose glimepiride & metformin hydrochloride (s", "voglibose glimepiride + metformin hydrochloride us", "glimepiride 1mg+metformin 500mg+voglibose 0.3 mg", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg g", "" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "668e77e853fc1c2298508399", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TENELIGOLD PIO 20/15 ", "description": "TENELIGOLD PIO 20/15 \nTeneligliptin & Pioglitazone\nIntroduction\nTENELIGOLD PIO 20/15 combines two antidiabetic medications, Teneligliptin and Pioglitazone, in a single formulation. This combination is designed to manage type 2 diabetes mellitus by targeting different aspects of glucose metabolism, thereby improving glycemic control in patients who are inadequately controlled with monotherapy or require dual therapy.\n\nComposition\n\nTeneligliptin: A dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances insulin secretion and reduces glucagon release, thereby lowering blood glucose levels.\nPioglitazone: A thiazolidinedione (TZD) that improves insulin sensitivity in peripheral tissues (muscle and adipose tissue) and reduces hepatic glucose production.\nMechanism of Action\n\nTeneligliptin: Inhibits the degradation of incretin hormones (GLP-1 and GIP), which play a key role in glucose-dependent insulin secretion and suppression of glucagon secretion.\nPioglitazone: Activates peroxisome proliferator-activated receptor gamma (PPAR-γ), leading to improved insulin sensitivity, enhanced glucose uptake in peripheral tissues, and reduced hepatic glucose production.\nIndications\nTENELIGOLD PIO 20/15 is indicated for:\n\nType 2 Diabetes Mellitus: Used to improve glycemic control in adults who are inadequately controlled with diet and exercise alone or with other antidiabetic medications.\nDosage and Administration\n\nThe typical dosage is one tablet of TENELIGOLD PIO 20/15 taken orally once daily, preferably with meals.\nDosage adjustments may be necessary based on individual patient response and tolerability.\nIt is important to adhere to the prescribed dosage regimen to achieve optimal glycemic control.\nSide Effects\nCommon side effects may include:\n\nHypoglycemia (especially when used in combination with insulin or sulfonylureas)\nEdema (fluid retention)\nWeight gain\nHeadache\nNasopharyngitis (common cold)\nMore severe side effects can include:\n\nHeart failure (especially in patients with pre-existing cardiovascular disease)\nHepatic dysfunction (monitor liver function tests periodically)\nBone fractures (especially in women)\nPrecautions\n\nHeart Failure: Use with caution in patients with a history of heart failure or other cardiovascular diseases.\nBladder Cancer: Pioglitazone has been associated with an increased risk of bladder cancer; therefore, it should be used cautiously in patients with a history of bladder cancer or with risk factors.\nLiver Function: Monitor liver function tests before starting treatment and periodically thereafter, as Pioglitazone may cause hepatic dysfunction.\nPregnancy and Lactation: Use during pregnancy and lactation should be avoided unless the potential benefits outweigh the risks.\nDrug Interactions\n\nInsulin/Sulfonylureas: Increased risk of hypoglycemia when used concomitantly with insulin or sulfonylureas.\nGemfibrozil: May increase Pioglitazone levels, requiring dose adjustment.\nCYP2C8 Inhibitors (e.g., Gemfibrozil): May increase Pioglitazone concentrations, necessitating monitoring for adverse effects.\nConclusion\nTENELIGOLD PIO 20/15 offers a dual-action approach to managing type 2 diabetes mellitus by combining Teneligliptin and Pioglitazone. This combination helps improve glycemic control through different mechanisms: enhancing insulin secretion and sensitivity. It is crucial to use this medication under the guidance of a healthcare professional to optimize treatment outcomes while minimizing the risk of side effects. Regular monitoring for efficacy and safety parameters, including blood glucose levels and potential adverse effects, is essential for managing diabetes effectively with TENELIGOLD PIO 20/15.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n\n", "price": 149.0, "discountamount": 44.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "key role", "one tablet", "Weight gain", "common cold", "risk factors", "dual therapy", "Heart failure", "increased risk", "dosage regimen", "typical dosage", "Bladder Cancer", "Bone fractures", "adipose tissue", "TENELIGOLD PIO", "glucose uptake", "dose adjustment", "fluid retention", "glucagon release", "DPP-4) inhibitor", "safety parameters", "CYP2C8 Inhibitors", "Drug Interactions", "incretin hormones", "different aspects", "Regular monitoring", "treatment outcomes", "Dosage adjustments", "peripheral tissues", "single formulation", "glucagon secretion", "potential benefits", "glucose metabolism", "insulin sensitivity", "Pioglitazone levels", "Hepatic dysfunction", "Common side effects", "different mechanisms", "dual-action approach", "liver function tests", "blood glucose levels", "dipeptidyl peptidase-4", "healthcare professional", "optimal glycemic control", "type 2 diabetes mellitus", "More severe side effects", "potential adverse effects", "hepatic glucose production", "Pioglitazone concentrations", "individual patient response", "two antidiabetic medications", "other cardiovascular diseases", "other antidiabetic medications", "existing cardiovascular disease", "glucose-dependent insulin secretion", "peroxisome proliferator-activated receptor gamma" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1935, "imageuri": "https://productimages.withfloats.com/actual/668e77ebf07c99c3af8e6d67.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668e77ebf07c99c3af8e6d67.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-10T12:00:40.528Z", "updatedon": "2024-07-10T12:00:40.528Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/teneligold-pio-20-15-/1935", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TENELIGOLD PIO 20/15 ", "category": "DIABETIC RANGE", "tags": [ "teneligliptin + pioglitazone brand name", "Zita Plus Pio", "Teneligliptin + Pioglitazone Metformin", "Zita Piomet 1000", "Teneligliptin 20 MG and Pioglitazone 15 MG tablets", "Dapagliflozin", "Zita Piomet 500" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "668d24ff75f1701d34699e32", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "GLICLAGLAZE 80 ", "description": "GLICLAGLAZE 80 \nGliclazide (80mg)\nOverview\nGLICLAGLAZE 80 is an oral medication containing Gliclazide at a dosage of 80 mg. Gliclazide belongs to the class of drugs known as sulfonylureas and is primarily used to manage type 2 diabetes mellitus. It helps control blood sugar levels by stimulating the release of insulin from the pancreatic beta cells. GLICLAGLAZE 80 is an effective treatment option for individuals who require oral hypoglycemic therapy to maintain optimal blood glucose levels.\n\nBenefits of Gliclazide\n\nBlood Sugar Control\n\nGliclazide effectively lowers blood glucose levels by increasing insulin secretion.\nHelps prevent complications associated with diabetes, such as neuropathy, nephropathy, and retinopathy.\nReduced Risk of Hypoglycemia\n\nCompared to some other sulfonylureas, Gliclazide has a lower risk of causing hypoglycemia (low blood sugar levels).\nIt provides a balanced approach to managing blood sugar without causing excessive drops in glucose levels.\nCardiovascular Benefits\n\nStudies suggest that Gliclazide may have a protective effect on the cardiovascular system.\nIt may reduce the risk of cardiovascular events in diabetic patients, promoting overall heart health.\nImproved Glycemic Control\n\nHelps achieve and maintain target HbA1c levels, reflecting long-term glycemic control.\nCan be used in combination with other oral antidiabetic agents or insulin to enhance its effectiveness.\nUsage and Dosage\nGLICLAGLAZE 80 should be taken as prescribed by a healthcare professional. The typical starting dose is 40 to 80 mg daily, which can be adjusted based on the patient's blood glucose response. It is usually taken with meals to maximize its effectiveness and minimize gastrointestinal side effects. Consistent use and adherence to prescribed dosage are crucial for optimal results.\n\nIndications for Use\n\nType 2 Diabetes Mellitus: GLICLAGLAZE 80 is indicated for the management of type 2 diabetes in patients who cannot achieve adequate glycemic control through diet and exercise alone.\nCombination Therapy: It can be used in conjunction with other oral hypoglycemic agents or insulin to achieve better blood sugar control.\nSide Effects\nGLICLAGLAZE 80 is generally well-tolerated. However, some patients may experience side effects, including:\n\nHypoglycemia: Although less common, low blood sugar can occur, especially if meals are skipped or combined with excessive physical activity.\nGastrointestinal Issues: Nausea, abdominal pain, and diarrhea may occur but are usually mild and transient.\nAllergic Reactions: Rarely, allergic reactions such as skin rash, itching, or hives may occur.\nPrecautions and Contraindications\n\nLiver and Kidney Impairment: Patients with severe liver or kidney disease should use GLICLAGLAZE 80 with caution, as it may require dose adjustments.\nPregnancy and Lactation: Gliclazide is not recommended during pregnancy or breastfeeding. Alternative treatments should be considered.\nDrug Interactions: Inform your healthcare provider about all medications and supplements you are taking, as Gliclazide can interact with other drugs, potentially altering its effectiveness.\nConclusion\nGLICLAGLAZE 80 is a reliable and effective oral medication for managing type 2 diabetes mellitus. By stimulating insulin secretion, it helps control blood sugar levels, reducing the risk of diabetes-related complications. Its balanced approach to glycemic control, combined with potential cardiovascular benefits, makes GLICLAGLAZE 80 a valuable addition to diabetes management plans. Under the guidance of a healthcare professional, GLICLAGLAZE 80 can significantly improve the quality of life for individuals with type 2 diabetes, promoting better long-term health outcomes.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n", "price": 265.0, "discountamount": 79.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "skin rash", "lower risk", "40 to 80 mg", "other drugs", "severe liver", "Reduced Risk", "Consistent use", "kidney disease", "abdominal pain", "excessive drops", "optimal results", "dose adjustments", "diabetic patients", "insulin secretion", "valuable addition", "Drug Interactions", "Kidney Impairment", "protective effect", "balanced approach", "Allergic Reactions", "healthcare provider", "Combination Therapy", "other sulfonylureas", "Blood Sugar Control", "target HbA1c levels", "overall heart health", "cardiovascular events", "cardiovascular system", "typical starting dose", "pancreatic beta cells", "Alternative treatments", "blood glucose response", "low blood sugar levels", "healthcare professional", "Gastrointestinal Issues", "type 2 diabetes mellitus", "diabetes management plans", "adequate glycemic control", "effective oral medication", "long-term health outcomes", "oral hypoglycemic therapy", "long-term glycemic control", "effective treatment option", "excessive physical activity", "optimal blood glucose levels", "gastrointestinal side effects", "diabetes-related complications", "other oral hypoglycemic agents", "other oral antidiabetic agents", "potential cardiovascular benefits" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1922, "imageuri": "https://productimages.withfloats.com/actual/668d2505c34ba6457aa3fb4d.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668d2505c34ba6457aa3fb4d.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-09T11:54:39.186Z", "updatedon": "2024-07-09T11:54:39.186Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/gliclaglaze-80-/1922", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLICLAGLAZE 80 ", "category": "DIABETIC RANGE", "tags": [ "Gliclazide 80mg side effects", "Gliclazide 80mg dosage", "Gliclazide 80mg Metformin 500mg", "Gliclazide 80mg price", "Gliclazide 80mg uses", "Gliclazide 80mg Uses in Hindi", "Gliclazide 80mg before or after meal" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6662cb8e161afa2274ff6309", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VOGLIGOLD 0.3 ", "description": "VOGLIGOLD 0.3 \nVoglibose (0.3mg)\nIntroduction to VOGLIGOLD 0.3\nVOGLIGOLD 0.3 is an oral medication designed to help manage type 2 diabetes mellitus by controlling blood sugar levels. It contains Voglibose, an alpha-glucosidase inhibitor that works by slowing the digestion and absorption of carbohydrates in the intestines. This mechanism helps prevent spikes in blood sugar levels after meals. VOGLIGOLD 0.3 is used alongside diet and exercise to improve glycemic control in adults with type 2 diabetes.\n\nKey Component and Mechanism of Action\nVoglibose 0.3mg\nVoglibose is a potent alpha-glucosidase inhibitor. It functions by inhibiting the alpha-glucosidase enzyme in the small intestine, which is responsible for breaking down complex carbohydrates into simple sugars. By inhibiting this enzyme, Voglibose slows down the conversion of carbohydrates into glucose, thereby reducing the postprandial (after-meal) rise in blood sugar levels.\n\nSlows Carbohydrate Absorption: By delaying the absorption of glucose, Voglibose helps to smooth out the postprandial blood glucose peaks.\nReduces Postprandial Hyperglycemia: It specifically targets the blood sugar spikes that occur after meals, making it an effective treatment for controlling postprandial hyperglycemia.\nBenefits of VOGLIGOLD 0.3\nEffective Postprandial Blood Sugar Control\nManages After-Meal Blood Sugar Levels: VOGLIGOLD 0.3 helps to manage and reduce the rise in blood sugar levels that occur after meals.\nComplementary Therapy: It can be used in combination with other antidiabetic medications such as metformin, sulfonylureas, or insulin to provide comprehensive glycemic control.\nAdditional Health Benefits\nWeight Neutral: Voglibose is generally weight neutral, making it a favorable option for patients concerned about weight gain associated with other diabetes medications.\nLow Risk of Hypoglycemia: When used alone, Voglibose has a low risk of causing hypoglycemia (low blood sugar), as it does not increase insulin secretion directly.\nHow to Use VOGLIGOLD 0.3\nDosage and Administration\nRecommended Dosage: The typical dosage of VOGLIGOLD 0.3 is one tablet taken three times a day, just before meals.\nAdministration: Take the tablet whole with a glass of water, just before starting your meal. This timing ensures that the medication works effectively by inhibiting the enzyme responsible for carbohydrate digestion.\nGuidelines for Optimal Use\nConsistent Use: For best results, take VOGLIGOLD 0.3 regularly at the same times each day as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regular monitoring of blood sugar levels is important to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/st-gliptin-dapa-100-10-134075", "price": 119.0, "discountamount": 35.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "dapa", "rise", "diet", "Order", "water", "EMAIL", "meals", "glass", "option", "timing", "Action", "adults", "gliptin", "patients", "exercise", "readings", "Low Risk", "metformin", "VOGLIGOLD", "Voglibose", "mechanism", "Guidelines", "conversion", "same times", "intestines", "one tablet", "Optimal Use", "weight gain", "combination", "information", "Adjustments", "Introduction", "Hypoglycemia", "sterisonline", "best results", "sterispharma", "sulfonylureas", "CALL/WHATSAPP", "simple sugars", "Key Component", "treatment plan", "typical dosage", "Administration", "Consistent Use", "Weight Neutral", "low blood sugar", "small intestine", "oral medication", "insulin secretion", "Regular monitoring", "Recommended Dosage", "blood sugar spikes", "effective treatment", "healthcare provider", "complex carbohydrates", "Complementary Therapy", "carbohydrate digestion", "Meal Blood Sugar Levels", "Carbohydrate Absorption", "alpha-glucosidase enzyme", "type 2 diabetes mellitus", "Postprandial Hyperglycemia", "Additional Health Benefits", "other diabetes medications", "comprehensive glycemic control", "other antidiabetic medications", "postprandial blood glucose peaks", "potent alpha-glucosidase inhibitor", "Effective Postprandial Blood Sugar Control" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1518, "imageuri": "https://productimages.withfloats.com/actual/667d3145422dd0be26724c0b.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d3145422dd0be26724c0b.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T08:57:50.904Z", "updatedon": "2024-06-27T09:30:42.497Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/vogligold-0-3-/1518", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VOGLIGOLD 0.3 ", "category": "DIABETIC RANGE", "tags": [ "voglibose 0.3mg price", "voglibose 0.3mg dosage", "voglibose 0.3mg brands in india" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6662c935a743fd2358222332", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VOGLIGOLD 0.2 ", "description": "VOGLIGOLD 0.2 \nVoglibose (0.2mg)\nIntroduction to VOGLIGOLD 0.2\nVOGLIGOLD 0.2 is a medication designed to manage type 2 diabetes mellitus by helping to control blood sugar levels. It contains Voglibose, an alpha-glucosidase inhibitor, which works by slowing down the digestion and absorption of carbohydrates from the intestines. This action helps to prevent spikes in blood sugar levels after meals. VOGLIGOLD 0.2 is used in conjunction with diet and exercise to improve glycemic control in adults with type 2 diabetes.\n\nKey Component and Mechanism of Action\nVoglibose 0.2mg\nVoglibose is a potent alpha-glucosidase inhibitor. It works by inhibiting the alpha-glucosidase enzyme in the small intestine, which is responsible for breaking down complex carbohydrates into simple sugars. By inhibiting this enzyme, Voglibose slows down the conversion of carbohydrates into glucose, thereby reducing the postprandial (after-meal) rise in blood sugar levels.\n\nSlows Carbohydrate Absorption: By delaying the absorption of glucose, Voglibose helps to smooth out the postprandial blood glucose peaks.\nReduces Postprandial Hyperglycemia: It specifically targets the blood sugar spikes that occur after meals, making it an effective treatment for controlling postprandial hyperglycemia.\nBenefits of VOGLIGOLD 0.2\nEffective Postprandial Blood Sugar Control\nManages After-Meal Blood Sugar Levels: VOGLIGOLD 0.2 helps to manage and reduce the rise in blood sugar levels that occur after meals.\nComplementary Therapy: It can be used in combination with other antidiabetic medications such as metformin, sulfonylureas, or insulin to provide comprehensive glycemic control.\nAdditional Health Benefits\nWeight Neutral: Voglibose is generally weight neutral, making it a favorable option for patients concerned about weight gain associated with other diabetes medications.\nLow Risk of Hypoglycemia: When used alone, Voglibose has a low risk of causing hypoglycemia (low blood sugar), as it does not increase insulin secretion directly.\nHow to Use VOGLIGOLD 0.2\nDosage and Administration\nRecommended Dosage: The typical dosage of VOGLIGOLD 0.2 is one tablet taken three times a day, just before meals.\nAdministration: Take the tablet whole with a glass of water, just before starting your meal. This timing ensures that the medication works effectively by inhibiting the enzyme responsible for carbohydrate digestion.\nGuidelines for Optimal Use\nConsistent Use: For best results, take VOGLIGOLD 0.2 regularly at the same times each day as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regular monitoring of blood sugar levels is important to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/vogligold-0-2-133456", "price": 89.0, "discountamount": 26.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "rise", "diet", "Order", "EMAIL", "meals", "glass", "water", "option", "action", "adults", "timing", "patients", "Low Risk", "exercise", "readings", "metformin", "VOGLIGOLD", "Voglibose", "Mechanism", "Guidelines", "intestines", "same times", "one tablet", "conversion", "Optimal Use", "weight gain", "conjunction", "Adjustments", "combination", "information", "Introduction", "Hypoglycemia", "sterisonline", "sterispharma", "best results", "simple sugars", "CALL/WHATSAPP", "Key Component", "sulfonylureas", "Weight Neutral", "typical dosage", "treatment plan", "Administration", "Consistent Use", "small intestine", "low blood sugar", "insulin secretion", "blood sugar spikes", "Recommended Dosage", "Regular monitoring", "healthcare provider", "effective treatment", "complex carbohydrates", "Complementary Therapy", "carbohydrate digestion", "Meal Blood Sugar Levels", "Carbohydrate Absorption", "alpha-glucosidase enzyme", "type 2 diabetes mellitus", "Postprandial Hyperglycemia", "Additional Health Benefits", "other diabetes medications", "comprehensive glycemic control", "other antidiabetic medications", "postprandial blood glucose peaks", "potent alpha-glucosidase inhibitor", "Effective Postprandial Blood Sugar Control" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1515, "imageuri": "https://productimages.withfloats.com/actual/667d34025e58b0758f70570b.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d34025e58b0758f70570b.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T08:47:49.18Z", "updatedon": "2024-06-27T09:42:22.871Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/vogligold-0-2-/1515", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VOGLIGOLD 0.2 ", "category": "DIABETIC RANGE", "tags": [ "voglibose side effects", "voglibose 0.2 mg side effects", "voglibose 0.2mg dosage" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }